# US 2026/0083699 A1 · Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083699 A1
- Document ID: US20260083699A1
- Status: Published application
- Kind: A1
- Application number: 19/409,215
- Filed: 2025-12-04
- Published: 2026-03-26
- Earliest claimed: 2021-08-06
- Assignees: Transcend Therapeutics, Inc.
- Applicants: Transcend Therapeutics, Inc.
- Inventors: Blake MANDELL; Martin STOGNIEW; Jennifer Louise SCHMIDT; Markus SEELIG
- Web page: https://patentgrep.com/patent/US20260083699A1

## CPC

- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

## Claims

### Claim at position 1

-70. (canceled)

### Claim 71

A method of treating post-traumatic stress disorder (PTSD) or anxiety in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound, wherein the compound is methylone (3,4-methylenedioxy-N-methylcathinone) or a pharmaceutically acceptable salt thereof.

### Claim 72 (depends on 71)

The method of claim 71, wherein the compound is a pharmaceutically acceptable salt of methylone.

### Claim 73 (depends on 72)

The method of claim 72, wherein the pharmaceutically acceptable salt of methylone is an acid addition salt.

### Claim 74 (depends on 73)

The method of claim 73, wherein the acid addition salt is methylone HCl.

### Claim 75 (depends on 71)

The method of claim 71, wherein the therapeutically effective amount corresponds to 50-1,000 mg of methylone.

### Claim 76 (depends on 71)

The method of claim 71, wherein the therapeutically effective amount corresponds to 100-300 mg of methylone.

### Claim 77 (depends on 71)

The method of claim 71, wherein the therapeutically effective amount corresponds to 150 mg of methylone.

### Claim 78 (depends on 71)

The method of claim 71, wherein the therapeutically effective amount corresponds to 150 mg of methylone administered as a single dose once per week.

### Claim 79 (depends on 71)

The method of claim 71, wherein the therapeutically effective amount corresponds to 250 mg of methylone.

### Claim 80 (depends on 71)

The method of claim 71, wherein the therapeutically effective amount is administered weekly.

### Claim 81 (depends on 71)

The method of claim 71, wherein the a therapeutically effective amount is administered orally.

### Claim 82 (depends on 71)

The method of claim 71, wherein the method is a method of treating PTSD and the subject has undergone prior treatment for PTSD.

### Claim 83 (depends on 71)

The method of claim 71, wherein the therapeutically effective amount is administered by administering an initial dose of the compound followed 30 minutes to 4 hours later by administering a second dose of the compound.

### Claim 84 (depends on 83)

The method of claim 83, wherein the second dose is 10% to 100% in amount of the initial dose.

### Claim 85 (depends on 83)

The method of claim 83, wherein the initial dose corresponds to 50-500 mg methylone.

### Claim 86 (depends on 83)

The method of claim 83, wherein the initial dose corresponds to 150 mg methylone.

### Claim 87 (depends on 83)

The method of claim 83, wherein the second dose corresponds to 25-250 mg methylone.

### Claim 88 (depends on 83)

The method of claim 83, wherein the second dose corresponds to 100 mg methylone.

### Claim 89 (depends on 83)

The method of claim 83, wherein the initial dose corresponds to 50-500 mg methylone and second dose corresponds to 25-250 mg methylone.

### Claim 90 (depends on 83)

The method of claim 83, wherein the initial dose corresponds to 150 mg methylone and the second dose corresponds to 100 mg methylone.

### Claim 91

A method of treating post-traumatic stress disorder (PTSD) or anxiety in a human subject in need thereof, comprising orally administering to the subject a therapeutically effective amount of a compound, wherein
the compound is methylone (3,4-methylenedioxy-N-methylcathinone) HCl;
the therapeutically effective amount corresponds to 100-300 mg of methylone; and
the therapeutically effective amount is administered weekly.

### Claim 92 (depends on 91)

The method of claim 91, wherein the therapeutically effective amount corresponds to 150 mg of methylone.

### Claim 93 (depends on 91)

The method of claim 91, wherein the therapeutically effective amount corresponds to 250 mg of methylone.

### Claim 94 (depends on 91)

The method of claim 91, wherein the method is a method of treating PTSD and the subject has undergone prior treatment for PTSD.

### Claim 95 (depends on 91)

The method of claim 91, wherein the therapeutically effective amount is administered by administering an initial dose of the compound followed 30 minutes to 4 hours later by administering a second dose of the compound.

### Claim 96 (depends on 95)

The method of claim 95, wherein the second dose is 10% to 100% in amount of the initial dose.

### Claim 97 (depends on 95)

The method of claim 95, wherein the initial dose corresponds to 150 mg methylone.

### Claim 98 (depends on 95)

The method of claim 95, wherein the second dose corresponds to 100 mg methylone.

### Claim 99 (depends on 95)

The method of claim 95, wherein the initial dose corresponds to 50-500 mg methylone and second dose corresponds to 25-250 mg methylone.

### Claim 100 (depends on 95)

The method of claim 95, wherein the initial dose corresponds to 150 mg methylone and the second dose corresponds to 100 mg methylone.
